Neil B. Minkoff, MD

November 15, 2021

Steps that need to be taken to address unmet needs and optimize outcomes for patients who have chronic kidney disease and type 2 diabetes.

November 15, 2021

An overview of therapies in the pipeline, including other nonsteroidal MRAs, that show potential in treating patients who have chronic kidney disease and type 2 diabetes.

November 15, 2021

A panel of clinicians react to limitations surrounding the use of SGLT2 inhibitors for patients with chronic kidney disease and type 2 diabetes.

November 11, 2021

Where data demonstrated by the FIDELIO-DKD study of finerenone for patients with chronic kidney disease may apply in routine clinical practice.

November 11, 2021

What to know in terms of the mechanism of action of non-steroidal MRA finerenone compared with other therapies used to treat patients with chronic kidney disease and type 2 diabetes.

November 04, 2021

George L. Bakris, MD, describes the design and results of the FIDELIO-DKD trial investigating the effect of finerenone on patients with chronic kidney disease.

November 04, 2021

Therapies used to help treat patients who have chronic kidney disease and type 2 diabetes.

October 28, 2021

Considerations for establishing balance for the care of patients with chronic kidney disease among all types of care settings.

October 28, 2021

What better testing strategies and newer quality measures can do to improve patient referrals to nephrologists for earlier intervention of chronic kidney disease.

October 21, 2021

Key takeaways from the National Kidney Foundation’s new HEDIS and MIPS quality measures for patients with chronic kidney disease and type 2 diabetes.